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Abstract
The use of candidate genes has increased the ability to identify genetic factors involved in diseases with complex and
multifactorial etiology. The surfactant proteins (SP) A and D are involved in host defense and inflammatory processes of the
lung, which are often components of pulmonary disease. Therefore, the SP-A and SP-D genes make particularly good
candidates to study factors contributing to pulmonary disease etiopathogenesis. Moreover, SP-A also plays a role in the
surface tension lowering abilities of pulmonary surfactant, which is essential for normal lung function. Although genetic
variability at the SP-D locus may exist among humans, allelic variants have not yet been characterized. On the other hand,
the human SP-A genes (SP-A1 and SP-A2) are characterized by genetically dependent splice variants at the 5P untranslated
region and allelic variants. The polymorphisms that give rise to SP-A1 and SP-A2 alleles are contained within coding regions,
potentially having an effect on protein function. There appears to be a correlation between SP-A genotype and SP-A mRNA
content. Furthermore, one SP-A2 allele (1A0) shown to associate with low SP-A mRNA levels is found with higher frequency
in a subgroup with respiratory distress syndrome. The evidence gathered thus far indicates that SP-A, possibly by interacting
with other surfactant components, may play a role (e.g. be a susceptibility factor) in the development of respiratory
disease. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Genetic analysis of complex disease
Linkage analysis has been used successfully to elu-
cidate the genetic cause of a number of diseases that
are inherited in a classic Mendelian fashion and are
the result of a mutation(s) in a single gene (e.g. cystic
¢brosis [1] and Huntington’s disease [2]). However, it
has become increasingly apparent that traditional
linkage analysis is not as useful in the identi¢cation
of the genetic components of diseases with complex
and multifactorial etiology (e.g. hypertension, diabe-
tes, or schizophrenia). Complex diseases are most
likely the result of multiple interactions between
both genetic and non-genetic factors (see Fig. 1). In-
complete penetrance, polygenic inheritance, and lo-
cus heterogeneity (reviewed in [3]) are among the
reasons that complex diseases often display pheno-
typic heterogeneity. The underlying complexity often
presents limitations for the use of traditional linkage
analysis because complex diseases do not exhibit
classic Mendelian recessive or dominant inheritance
attributable to a single gene locus [4]. Moreover, the
large multigenerational families necessary to perform
linkage analysis are most times not available.
In recent years, a number of methods have been
used to study the genetics of complex diseases includ-
ing association studies, transmission/disequilibrium
tests, a¡ected sib-pair analysis, and studies of twins.
Association studies [5] compare the frequency of an
allele between two populations: cases (unrelated in-
dividuals who have the disease) and controls (unre-
lated individuals who do not have the disease). If the
frequencies of certain alleles for a genetic locus di¡er
signi¢cantly between cases and controls, it is said
that the particular alleles are associated with the dis-
ease. One disadvantage of association studies is the
potential for false positives due to population admix-
ture (i.e. the populations under study are not genet-
ically homogeneous). The transmission/disequili-
brium test (TDT) can be used to help overcome
this limitation.
TDT analysis is based on the notion that a parent,
heterozygous for an allele associated with disease and
an allele not associated with disease, would transmit
the associated allele to the a¡ected o¡spring more
frequently than expected by chance [6]. Advantages
of TDT analysis include the use of the non-transmit-
ted parental allele as an internal control and the
ability to test for disease alleles that have modest
e¡ects. The latter may not be easily detected using
other methods [6^8].
Studies of a¡ected sib-pairs and of twins are also
useful approaches in the investigation of complex
diseases. The major advantage of a¡ected sib-pair
(ASP) analysis over traditional pedigree linkage anal-
ysis is that the ASP does not require assumptions
regarding the mode of disease inheritance. Also, in-
creased allele sharing among a¡ected relatives occurs
even in the presence of genetic heterogeneity, incom-
plete penetrance, phenocopy, and high frequency of
disease alleles. However, ASP and twin studies can
only detect major gene e¡ects whereas association
studies and TDT analysis can identify susceptibility
loci with a small or modest contribution to the etio-
pathogenesis of disease [5,6]. Moreover, TDT and
association studies, unlike a¡ected sib-pair or classi-
cal linkage analysis, do not require families with mul-
tiple a¡ected siblings. Furthermore, an extension of
the TDT can be used to address the possibility that
each genetic marker allele is associated with the dis-
ease to a di¡erent extent [8].
The genetic markers used in these various genetic
approaches are often microsatellites, nucleotide re-
peats of variable length that are found throughout
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the human genome. Recently, single nucleotide poly-
morphisms (SNPs) have also been suggested as useful
genetic markers [9]. However, the power of TDT
analysis and association studies is greatly increased
when polymorphisms (e.g. SNPs) within a candidate
gene are used [4,10]. A candidate gene is a gene that
by way of derangement of either its function or ex-
pression, as a result of a mutation or polymorphism,
could cause and/or modify the disease under study. It
is within this context that the genes encoding the
surfactant proteins (SP), particularly SP-A, have be-
come the focus of recent investigations into the ge-
netic causes of respiratory disease [3].
2. Pulmonary surfactant and disease
Pulmonary surfactant is a lipoprotein complex
synthesized by the lungs and is essential for normal
lung function (reviewed in [11]). Pulmonary surfac-
tant not only reduces the surface tension at the al-
veolar air liquid interface (thus preventing alveolar
collapse) but is also involved in host defense and
in£ammatory processes of the lung. The importance
of surfactant for normal lung function is exempli¢ed
by the fact that prematurely born babies de¢cient in
surfactant can develop respiratory distress syndrome
(RDS). The etiology of RDS is complex in that a
number of factors play a role in its development in-
cluding gestational age, race, sex, and the hormonal
milieu to which the fetus is exposed [3,12]. A genetic
contribution to the etiopathogenesis of RDS has
been suggested by an increased concordance of the
disease between monozygotic twins compared to di-
zygotic twins [13].
Alteration in pulmonary surfactant function, con-
tent, or composition has been associated with a num-
ber of other respiratory diseases such as adult respi-
ratory distress syndrome (ARDS), idiopathic
pulmonary ¢brosis (IPF), pulmonary bacterial and
viral infection, and alveolar proteinosis (AP) (re-
viewed in [14]). Like RDS, these diseases have com-
plex etiologies and probably result from a number of
environmental and genetic in£uences. It is less likely
that the genetic components of these diseases would
involve genes responsible for the production of sur-
factant lipids, because their gene products are not
lung speci¢c and therefore a change in their activity
could result in a broader phenotype (not limited to
the lungs). Thus, the lung speci¢c (for the most part)
genes encoding the surfactant proteins become good
candidate genes for diseases where abnormalities of
pulmonary surfactant function occur. The progres-
sion of many respiratory diseases involve in£amma-
tion and/or host defense. Therefore, the surfactant
proteins, namely SP-A and SP-D, known to have
immunomodulatory functions [14] are even more
likely to play a role in pulmonary disease pathogen-
esis.
3. SP-A, SP-D, and disease
The hydrophilic proteins of pulmonary surfactant,
SP-A and SP-D, are members of the C-type lectin
(also known as collectin) family of proteins in that
they contain a carbohydrate recognition domain as
well as a collagen-like domain [15]. Another member
of this protein family is the mannose binding protein
(MBP). Collectins are generally involved in the im-
mune process and it seems that SP-A and SP-D are
no exception. A number of studies have shown that
SP-A is involved in the activation of alveolar macro-
phages, proliferation of lymphocytes, and the pro-
duction of in£ammatory cytokines [14]. SP-A, by
way of its collectin characteristics, binds to bacteria
and viruses, leading to their elimination. Indeed,
SP-A ‘knockout’ mice have problems in clearing bac-
teria from their lungs [16]. SP-D has been shown to
interact with a number of the same pathogens as
SP-A; however, the exact immunomodulatory func-
tions of the two proteins may be distinct [17]. For
example, SP-D, but not SP-A, is able to cause agglu-
tination of a pathogenic yeast (C. neoformans) [18]
while SP-A, but not SP-D, is able to promote phag-
ocytosis of in£uenza A virus [19].
Interestingly, the levels of SP-A or SP-D are al-
tered in various diseases. Changes in SP-A levels are
seen in such diseases as IPF, Pneumocystis carinii
pneumonia, RDS, and ARDS [14]. Similarly, levels
of SP-D are increased in the serum and bronchoal-
veolar lavage £uid of patients with IPF, interstitial
pneumonia with collagen disease, and pulmonary al-
veolar proteinosis [20]. These ¢ndings suggest a cor-
relation between SP-A and/or SP-D levels with dis-
eases where host defense or in£ammatory processes
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are involved. Whether the alteration in SP-A or
SP-D levels is a contributing factor or merely a con-
sequence of disease is currently unknown.
4. The chromosome 10 collectin genes
The genes encoding SP-A and SP-D have been
mapped to human chromosome 10q21-q24 [21^23].
The human SP-A locus [24] contains two very similar
but non-identical genes, SP-A1 [25] and SP-A2 [26],
as well as a non-functional gene (i.e. a pseudogene)
[27]. It is generally thought that two SP-A1 gene
products and one SP-A2 gene product associate
through their collagen-like domains [28]. Six of these
trimers then combine to form the ¢nal SP-A multi-
mer that resembles a bouquet of £owers. Baboons
[29] are the only other species reported to have two
SP-A genes; rats, mice, rabbits, and dogs have only
one SP-A gene (that is not entirely identical to SP-A1
or SP-A2). The human SP-D locus, on the other
hand, contains a single gene [23].
SP-A1 and SP-A2 have been shown to be in link-
age disequilibrium [30], indicating close physical as-
sociation. This linkage was veri¢ed by the physical
and radiation hybrid mapping of the SP-A locus
(Fig. 2), which revealed that SP-A1 and SP-A2 are
separated by about 35^40 kb and are in opposite
transcriptional orientation [31]. The SP-A pseudo-
gene was found to be in between the two functional
genes and in the same orientation as SP-A2. The
fairly close proximity of SP-A1 and SP-A2, and their
opposite orientation hold the potential for shared cis-
acting regulatory elements.
Radiation hybrid mapping also showed that the
human SP-D locus is tightly linked to the SP-A locus
and lies closer to SP-A2 than to SP-A1 (Fig. 2).
SP-D is about 80^100 kb away from SP-A2 and is
more proximal (closer to the centromere) than the
SP-A locus [31]. The transcriptional orientation of
SP-D relative to either of the SP-A genes is currently
unknown.
Although the gene encoding another collectin,
MBP, has also been mapped to the long arm of
chromosome 10 [32], MBP is not linked to either
SP-D or SP-A [31]. The MBP locus, however, is
linked to a genetic marker (D10S567) about 25 cM
(25 000 kb) proximal to SP-D and SP-A [31]. The
organization of the SP-A, SP-D, and MBP loci is
illustrated in Fig. 2.
Nevertheless, the SP-A, SP-D, and MBP genes
share a number of characteristics such as similar ge-
nomic structural organization (see Fig. 3) and inter-
rupted glycine codons [23,32]. They also share the
Fig. 1. Schematic representation of genetic and non-genetic in-
teractions in the development of complex disease. Most diseases
are multifactorial in that their development is a result of multi-
ple interactions between the environment (E1, E2, and E3) and
genetic factors, such as disease susceptibility genes (G1, G2, and
G3) and genes that modify disease expression (M1, M2, and
M3). Double head arrows indicate interaction. Box represents
the entire spectrum of disease phenotype. Triangles represent
phenotypic subgroups (P1, P2, and P3) of a given disease, and
the overlap of the triangles indicates that distinctions between
subgroups may be dependent upon disease severity or stage.
(From [3] with permission.)
Fig. 2. Organization of the chromosome 10 collectin locus. Physical and radiation hybrid mapping revealed that SP-D, SP-A2, SP-A
pseudogene, and SP-A1 are tightly linked. The gene for MBP, although structurally related to SP-D and SP-A, is not linked to either
locus as indicated by the break in the line. P represents the SP-A pseudogene, and C and T represent the centromere and telomere, re-
spectively. The arrows indicate transcriptional orientation.
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possibility of evolving through the recombination of
an ancient non-¢brillar collagen gene and a gene that
codes for carbohydrate binding [23,32]. Moreover, a
correspondence between spatial distance and phylo-
genetic tree data appears to exist ; for example, SP-D,
which is more related to SP-A than MBP in evolu-
tion [21], is also physically closer to SP-A than
MBP.
The physical linkage of SP-D, SP-A2, SP-A pseu-
dogene, and SP-A1 greatly improves the ability to
perform genetic studies, because polymorphisms in
any of these loci can be combined and used together
in the form of haplotypes.
5. Complexity of the human SP-A genes
As noted in Fig. 3, each functional SP-A gene ex-
hibits extensive complexity. This complexity includes
splice variability of 5P untranslated (5PUT) exons,
allelic variability (based on polymorphisms within
coding regions), and sequence variability within the
3PUT region. SP-D splice or allelic variants have not
yet been described; however, Crouch et. al. [23] have
noted di¡erences between SP-D genomic clones and
the published cDNA SP-D sequence. Although the
possibility for SP-D allelic variation does exist, SP-D
alleles have not yet been characterized; thus we focus
our attention below on the genetic variability of
SP-A.
5.1. SP-A splice variants
Each SP-A gene has a number of 5PUT exons that
splice in di¡erent con¢gurations giving rise to a num-
ber of di¡erent SP-A1 and SP-A2 transcripts [33], as
shown in Fig. 4A,B (some rare transcripts [33,34] are
not shown). The most common splice variant of
SP-A1, the ADP transcript, is observed at a fre-
quency of approx. 0.8 [33]. The most common splice
variants of SP-A2, the ABD and ABDP transcripts,
are observed with varied frequency among humans
[33,35]. This variation depends on the SP-A2 geno-
type of the individual, and may be accounted for by
a single nucleotide change at the splice recognition
site and another one at the extended splice recogni-
tion site sequence (Fig. 4C). The former nucleotide
change (at the splice recognition site) results in splice
di¡erences among SP-A2 alleles with some alleles
producing only the ABDP transcript and others pro-
ducing both the ABD and ABDP transcripts. Specif-
ically, at the fourth untranslated exon, SP-A2 alleles
1A0 and 1A1 have two potential splice sites, D and
DP (Fig. 4C), whereas alleles 1A and 1A2 have only
one possible splice site, DP [35]. The second nucleo-
tide change (at the extended splice recognition site)
results in splice transcript preference, with the ABD
transcripts being preferred over the ABDP transcripts
when both splice sites (D and DP) are present, which
is the case for the 1A0 and 1A1 alleles. This prefer-
ence leads to an abundance of ABD transcripts and
Fig. 3. Genomic structural organization of the collectin genes (SP-A, SP-D, and MBP) located on human chromosome 10. Light gray
boxes represent untranslated exons. Black boxes indicate exons encoding the collagen-like domain and hatched boxes indicate exons
encoding the carbohydrate recognition domain. SP-A represents either SP-A1 or SP-A2. The nature of the SP-A variability (splice or
allelic variants) is noted above the SP-A gene while coding exons (I^IV) are numbered below. SP-A allelic variants are classi¢ed based
on nucleotide di¡erences within coding regions. Sequence variability within the SP-A 3P untranslated (3PUT) region has also been ob-
served.
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may be accounted for by nucleotide di¡erences at the
¢fth position 5P (noted with ‘+’ in Fig. 4C) from the
D and DP sites [35]. The consensus sequence for the
splice recognition site (shown at the bottom of Fig.
4C) indicates that a pyrimidine, a T (the case for the
D site), is preferred over a purine, an A (the case for
the DP site).
The SP-A1 and SP-A2 transcripts are translated
both in vitro [33] and in vivo [36], as assessed by
the presence of these messages in polysomes. Cur-
rently, it is not entirely clear whether the relative
e⁄ciency of translation for the various SP-A tran-
scripts is controlled by speci¢c regulatory factors or
even whether e⁄ciency of translation is altered under
compromised conditions (where presumably an im-
balance of key regulatory molecules occurs). Never-
theless, the available data [34,36] suggest that if
translation is a control point for SP-A gene regula-
tion it is unclear whether translation would be af-
fected by the characteristics of the splice variants
alone. In other words, control of translation may
come about by the interaction of speci¢c SP-A splice
variants and other factors.
We speculate that variability at the transcript level
re£ects an example of genetic parsimony (i.e. genetic
Fig. 4. 5P splice variants of the SP-A1 and SP-A2 genes. (A)
The names of the transcripts arising from alternate splicing of
the 5PUT exons are shown. Designations are of Karinch and
Floros [33] and in parentheses are those of McCormick et al.
[34]. There are three transcription start sites for SP-A1 (see be-
low) and *A represents transcripts derived from any of the
three start sites. SP-A2 has only one transcription start site (see
below) [33]. (B) Schematic representation of 5PUT exons A^D.
Bent arrows show the relative positions of the three SP-A1
transcription start sites (A, AP, and AQ). The transcription start
site for SP-A2 corresponds to start site A of SP-A1 (plus one
additional 5P nucleotide). The shaded boxes represent exons or
portions of exons found in the major SP-A1 or SP-A2 tran-
scripts. Arrows point to the alternate splice sites. Hatched box
represents coding exon I. (C) Sequence comparison among
SP-A2 alleles shows the presence of two potential splice sites
(D and DP) for the 1A0 and 1A1 alleles and the presence of
one splice site (DP) for the 1A and 1A2 alleles. The consensus
extended splice sequence is also shown. For alleles 1A0 and
1A1 the ¢fth nucleotide 5P of the DP splice site, which is a pu-
rine (A), and the ¢fth nucleotide (T) 5P of the D splice site,
which is a pyrimidine (T), as well as the ¢fth nucleotide (Y) of
the consensus splice sequence, are marked with a cross (+). Y
represents a pyrimidine and N represents any nucleotide. A pyr-
imidine in the ¢fth position from the actual splice site is pre-
ferred over a purine. This preference may account for the ob-
served high (s 1) ABD/ABDP ratio for the 1A0 and 1A1 alleles
[35].
Fig. 5. SP-A1 and SP-A2 alleles. Allelic designations for SP-A1
and SP-A2 are based on di¡erences within coding regions. The
positions of the relevant amino acids are at the bottom of the
¢gure. The ‘core’ amino acids, that distinguish SP-A1 from SP-
A2, are boxed. The 6A5 and 1A4 alleles are described in [40]
and the remaining in [30].
BBADIS 61781 2-11-98
J. Floros, R.R. Hoover / Biochimica et Biophysica Acta 1408 (1998) 312^322 317
economy), where stability at the gene level is main-
tained but a number of variable forms evolve (i.e.
alternatively spliced transcripts). These variable
forms can then be subjected to a variety of regula-
tory mechanisms that can modulate the response to
various stimuli and at the same time minimize per-
turbation of function.
5.2. SP-A alleles
A number of studies have shown extensive varia-
bility in SP-A mRNA levels [35,37] and SP-A protein
content [38,39] among individuals. It is possible that
this variability is a consequence of genetic heteroge-
neity. Based on the available coding sequences for
each SP-A gene, a number of alleles have been char-
acterized [30,40]. To date, ¢ve alleles for SP-A1 (6A,
6A2, 6A3, 6A4, and 6A5) and six alleles for SP-A2
(1A, 1A0, 1A1, 1A2, 1A3, and 1A4) have been char-
acterized (see Fig. 5). The alleles of SP-A1 are dis-
tinguished from those of SP-A2 by a ‘core’ of invar-
iant nucleotides or amino acids in coding exon II
[33]. Alleles of either gene are distinguished from
one another by nucleotide di¡erences throughout
the coding region [30,40] that produce changes in
the amino acid sequence (Fig. 5). The frequencies
of the SP-A alleles in the population are presented
in Fig. 6. The most common SP-A1 allele is 6A2 and
the most common SP-A2 allele is 1A0 [30]. Presently,
it is unknown whether there are functional di¡eren-
ces among the alleles; however, changes in either the
collagen-like domain or carbohydrate recognition
domain could a¡ect trimerization or host defense
functions.
Recently, an association has been made between
mRNA content and the most frequent genotype,
6A26A21A01A0 [35,40]. This genotype appears to
correlate with low to moderate levels of mRNA con-
tent, suggesting that either one or both (1A0, 6A2)
alleles are ‘low producers’. Based on the SP-A1 to
SP-A2 ratio of mRNA content, the 1A0 allele ap-
pears to be the one that correlates with low mRNA
levels compared to 6A2, and probably compared
to most (if not all) other SP-A alleles [35]. Of inter-
est, this (1A0) ‘low producing’ allele is found with
higher frequency in a subgroup of RDS [41] (see
below), raising the speculation that a prematurely
born infant with 1A0 genotype is at a higher risk
of developing RDS compared to the gestational
age-matched counterpart with a di¡erent SP-A2 ge-
notype.
6. RDS and surfactant protein polymorphisms
The etiology of RDS is likely to be multifactorial
and/or multigenic. Several factors play a role in the
development of the disease and evidence exists for a
genetic contribution (in at least certain cases) [3,12].
Therefore RDS, like other complex diseases, can re-
sult from interactions among disease causing genes,
the environment and/or modi¢er genes (Fig. 1). Dif-
ferent or overlapping sets of interactions are thought
to be responsible for (or underlie) each phenotypic
RDS subgroup. To identify the genetic contribution
in diseases with complex etiology (such as RDS) it is
important to study well characterized phenotypic
subgroups. Subgrouping (e.g. severity for hyperten-
sion or age of onset for Alzheimer’s disease), has
facilitated the identi¢cation of genetic components
for other complex diseases [4].
In the context of Fig. 1, and because the surfactant
proteins play important roles in surfactant physiol-
ogy and lung host defense, the hypothesis that the
Fig. 6. SP-A1 and SP-A2 allele frequencies in the population.
The 6A2 and the 1A0 alleles are the most frequent SP-A1 and
SP-A2 alleles, respectively. Data for 6A5 and 1A4 are not avail-
able, but these alleles are rare and their frequencies are ex-
pected to be very low.
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surfactant proteins are contributors to the etiology of
RDS is being examined. Association studies have
shown that the frequency of a polymorphism in in-
tron 4 of the SP-B gene [42] and the frequency of the
1A0 allele of the SP-A2 gene are higher in a sub-
group of RDS [41] (Fig. 7). Although an association
between an allele of each locus (SP-B or SP-A) and
RDS is observed, the frequency of the combined
polymorphisms in the RDS population is signi¢-
cantly higher [41] (Fig. 7). More importantly, the
nature of the increased frequency of the combined
polymorphisms appears to be that of synergism
rather than addition, suggesting an interaction be-
tween the SP-A and SP-B loci [41]. Interaction be-
tween two unlinked loci with gene products that in-
teract functionally (such as SP-A and SP-B) has also
been observed in other systems [43].
In light of an observed correlation between levels
of SP-A and severity of RDS [44], it is rather intrigu-
ing that the SP-A2 allele (1A0), shown to associate
with low to moderate mRNA content, is found with
higher frequency in RDS (Fig. 8). Moreover, reduced
levels of SP-A as well as of SP-B and SP-C have also
been noted by immunohistochemistry of lung tissues
from babies that died from RDS [45,46].
7. Lessons from the mannose binding protein
As members of the collectin family, SP-A and
SP-D share structural and functional similarities
with MBP. In this context, it is of interest to note
that certain MBP alleles have been shown to associ-
ate with diseases involving infection and in£amma-
tion. Associations have been found between MBP
alleles and systemic lupus erythematosus [47], persis-
tent childhood infections [48], and chronic hepatitis
B infection [49]. One MBP allele, MBPD (resulting
from a polymorphism at codon 54 that changes
a glycine to an aspartate), is dysfunctional [50].
Although the MBPD allele retains the collectin abil-
ity to form multimers and bind bacteria, it cannot,
unlike the wild type MPB allele, activate the comple-
ment cascade [50]. Thus it appears that, within the
population, MBP alleles exist that have di¡erent
functional capabilities; such a situation may also be
true for SP-A and/or SP-D.
Fig. 8. Summary of observations concerning the 1A0 allele.
Fig. 7. Association of 1A0 with RDS. The frequencies of an
SP-B variant and the 1A0 allele either singly or in combination
in a control population and a subgroup of RDS population are
shown. Note the synergistic increased frequency in RDS of the
combined polymorphisms. (Adapted from [41] with permission.)
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8. Unresolved issues and future perspectives
A signi¢cant percentage (s 30%) of the genetic
loci that have been studied thus far are polymorphic.
A locus is said to be polymorphic if the less frequent
allele(s) is found in the population at a frequency of
at least 0.01 and the heterozygotes with that partic-
ular allele occur at a frequency of 0.02. Stable poly-
morphisms can be used as markers of genetic diver-
sity, and thus they can play a very important role in
the identi¢cation of genetic factors that may contrib-
ute to a particular trait or disease [51].
Furthermore, current wisdom suggests that most
(if not all) of the stable polymorphisms are the result
of selection for advantageous alleles, although in
most cases the selective pressures are currently un-
known. In the case of the human SP-A locus, it is
clear that both functional SP-A genes are polymor-
phic. The distribution of SP-A1 and SP-A2 alleles,
shown in Fig. 6, indicates that the most frequent
alleles are 6A2 and 1A0 [30]. These alleles have
been shown to associate with low to moderate total
SP-A mRNA content [35,40], and the 1A0 allele is
found in higher frequency in a subgroup of the RDS
population [41]. If one assumes that the mRNA con-
tent re£ects protein levels, the observed higher fre-
quency of 6A2 and 1A0 alleles in the general popu-
lation is counterintuitive. In other words, the
selective advantage for the increased frequency of
the ‘low or moderately producing alleles’ is not read-
ily obvious.
However, SP-A is involved in two major groups of
functions. One group of functions involves the sur-
face-tension lowering properties of surfactant. The
other group relates to innate host defense and in-
£ammatory processes of the lung. In the former
role, SP-A appears to be important only when vari-
ous cellular factors or other surfactant components
that are necessary for optimal surfactant function are
not at optimal concentrations [52,53]. In this circum-
stance one can speculate that the ‘low or moderately
producing’ SP-A alleles are not advantageous for the
prematurely born infant. However, such alleles must
be advantageous (as judged by their high frequency
in the population) in some other role of SP-A. One
may argue that this other role is host defense and/or
in£ammatory processes of the lungs. Conversely, the
‘high producing’ alleles may be disadvantageous with
regards to innate host defense and in£ammatory
processes of the lung but advantageous for the sur-
face-tension lowering properties of surfactant.
One good example of a stable or balanced poly-
morphism is the allele(s) of hemoglobin responsible
for the sickle trait. Homozygous individuals for the
‘sickle’ allele are a¡ected by a severe hemolytic ane-
mia and usually die before they reach reproductive
age whereas heterozygous individuals (carriers) are
more resistant to malaria. The ‘sickle’ allele is main-
tained in the population and is found in high fre-
quency in parts of the world where malaria infection
is common. In other words, the small selective ad-
vantage (increase of biological ¢tness) of heterozy-
gotes has outweighed the major disadvantage (death)
of homozygotes and has thus provided the necessary
pressure to maintain the ‘sickle’ allele in high fre-
quency in malaria a¡ected regions.
Therefore, it is possible that the high frequency of
the ‘low/moderately producing’ SP-A alleles re£ect a
selective advantage as a result of an increased bio-
logical ¢tness. To assess the validity of such specula-
tion, and to explore others, it will be necessary to
develop reagents in order to measure each SP-A
gene product individually and to determine whether
mRNA levels re£ect protein levels. We need to inves-
tigate what happens when an imbalance occurs with
regard to the content of each SP-A gene product. We
will also need to study the regulation and the func-
tion of each allele of each SP-A gene. By doing so we
will gain insight into the potential role of SP-A al-
leles in the susceptibility of various diseases. We also
need to understand how the products of a particular
set of alleles at two separate unlinked loci (e.g. SP-A
and SP-B) can interact to produce an unexpected
result with regard to a given phenotype (an example
of epistasis). Finally, we need to understand the com-
plementary and overlapping roles of SP-A and SP-D
in innate host defense and the potential contribution
(if any) of SP-A and SP-D alleles to the susceptibility
of disease.
9. Final thoughts
The bene¢t derived from the cumulative knowl-
edge of multidisciplinary approaches will reach new
heights regarding the hydrophilic surfactant proteins.
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Our thinking and problem solving capacities will be
pleasantly challenged as never before. As parts of the
puzzle become clearer, unanticipated paths and ques-
tions will most undoubtedly come to view and refuel
our scienti¢c curiosity.
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